ZAS Corporation Successfully Launches Celltrion Biosimilars in Bangladesh

We are proud to announce the successful launch of Celltrion’s biosimilar products in Bangladesh, marking a significant milestone in our commitment to advancing healthcare in the nation. This launch represents not just the introduction of new treatments but the beginning of a new era in patient care, driven by innovation and quality.

Our launch campaign was designed to build anticipation and educate both healthcare professionals and the public about the importance and impact of biosimilars. Over the past few weeks, we have shared a series of video content on our social media channels, each contributing to the broader narrative of this groundbreaking introduction.

1. Launching Teaser

We kicked off the campaign with a teaser video, sparking curiosity and excitement across our audience as we hinted at the coming transformation. Watch it here.

2. Launching Content

Following the teaser, we unveiled our full launching video, highlighting the arrival of Celltrion’s biosimilars in Bangladesh and what this means for the future of healthcare in our country. Watch the launch video here.

3. Story Behind Launching

To provide deeper insight, we shared the story behind this significant launch. This video features our biosimilar portfolio experts discussing the reasons for choosing Celltrion and the meticulous process that brought these treatments to Bangladesh. Discover the story here.

4. Healthcare Professionals’ Thoughts

In collaboration with some of the country’s leading oncologists, we published a series of videos where these renowned healthcare professionals shared their thoughts on the importance of monoclonal antibodies (MABs), congratulated ZAS Corporation on this successful launch, and expressed their best wishes for future developments. Watch their insights:

  • Thoughts from Prof. Dr. Md. Moarraf Hossen
  • Thoughts from Prof. Dr. Md. Mofazzel Hossain
  • Thoughts from Prof. Dr. Md. Ehteshamul Hoque

Through these videos, we have not only introduced a new range of biosimilars but also emphasized our ongoing dedication to elevating the standard of care in Bangladesh. This launch is a testament to our unwavering commitment to bringing world-class healthcare solutions to those who need them most.

As we move forward, ZAS Corporation remains focused on driving innovation and improving lives. We are excited about the journey ahead and look forward to continuing our mission of making a meaningful impact on healthcare in Bangladesh.

Scroll to Top